Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
September 01 2009 - 8:55AM
PR Newswire (US)
BALTIMORE, Sept. 1 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company
engaged in the development of advanced preclinical platforms and
tumor specific data to enhance the value of oncology drugs, has
established yet another agreement with a large biotechnology
company for the evaluation of a novel oncology therapeutic in
Champions' Biomerk Tumorgraft(TM) platform. By maintaining the
fundamental genotypic features of the original human tumor along
with the stromal components, the Biomerk Tumorgraft preclinical
platform enables identification of the most promising development
path for a compound in terms of indication, drug combination, and
target patient population. The platform also has the potential to
identify gene pathways of response and resistance as well as
prognostic molecular biomarkers. "We are excited to continue the
growth of our impressive client base and begin working with one of
the most respected global leaders in the discovery and development
of novel therapies," said Doug Burkett, Ph.D., President of
Champions Biotechnology, Inc. "Studies suggest that evaluation of
oncology compounds through our Biomerk Tumorgraft platform will
lead to more successful and efficient clinical development. The
value-added by an optimally targeted, more efficient clinical path
can result in cost savings, improved clinical and commercial
success and significantly more years of patent life following
commercialization." About Champions Biotechnology, Inc. Champions
Biotechnology, Inc. is engaged in the development of advanced
preclinical platforms and tumor specific data to enhance and
accelerate the value of oncology drugs. The Company's Preclinical
Platform is a novel approach based upon the implantation of primary
human tumors in immune deficient mice followed by propagation of
the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner
that preserves the biological characteristics of the original human
tumor. Early studies suggest that unlike traditional xenografts,
these Tumorgrafts closely reflect human cancer biology and their
response to drugs is predictive of clinical outcomes in cancer
patients. Champions Biotechnology leverages its preclinical
platform to evaluate drug candidates and to develop a portfolio of
novel therapeutic candidates. As drugs progress through early stage
development, the Company plans to sell, partner or license them to
pharmaceutical and/or biotechnology companies, as appropriate. The
Company also offers its predictive preclinical platform and tumor
specific data to physicians for personalized patient care and to
companies for evaluation of oncology drugs in models that integrate
prognostic testing with biomarker discovery.
http://www.championsbiotechnology.com/http://www.personalizedcancertreatment.com/
This press release contains "forward-looking statements" (within
the meaning of the Private Securities Litigation Act of 1995) that
inherently involve risk and uncertainties. Champions Biotechnology
generally uses words such as "believe," "may," "could," "will,"
"intend," "expect," "anticipate," "plan," and similar expressions
to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company's actual
results could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors. See
Champions Biotechnology's Form 10-K for the fiscal year ended April
30, 2009 for a discussion of such risks, uncertainties and other
factors. Although the Company believes the expectations reflected
in the forward-looking statements are reasonable, they relate only
to events as of the date on which the statements are made, and
Champions Biotechnology's future results, levels of activity,
performance or achievements may not meet these expectations. The
Company does not intend to update any of the forward-looking
statements after the date of this press release to conform these
statements to actual results or to changes in Champions
Biotechnology's expectations, except as required by law.
DATASOURCE: Champions Biotechnology, Inc. CONTACT: The Investor
Relations Group, Investor Relations, James Carbonara, or Public
Relations, Susan Morgenbesser, +1-212-825-3210 Web Site:
http://championsbiotechnology.com/
Copyright